Werewolf Therapeutics (NASDAQ:HOWL) Price Target Cut to $4.00 by Analysts at JMP Securities

Werewolf Therapeutics (NASDAQ:HOWL) had its price objective reduced by JMP Securities from $12.00 to $4.00 in a report issued on Tuesday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $1.35 on Tuesday. Werewolf Therapeutics has a 12 month low of $1.31 and a 12 month high of $8.19. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $60.16 million, a price-to-earnings ratio of -0.88 and a beta of 0.38. The stock’s 50 day moving average is $1.75 and its 200-day moving average is $2.10.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently made changes to their positions in HOWL. Millennium Management LLC grew its holdings in Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after purchasing an additional 544,881 shares during the period. PFM Health Sciences LP lifted its position in shares of Werewolf Therapeutics by 4.9% during the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after buying an additional 157,673 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Werewolf Therapeutics by 410.5% during the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after acquiring an additional 107,900 shares during the period. Renaissance Technologies LLC increased its holdings in Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after acquiring an additional 86,800 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Werewolf Therapeutics in the 2nd quarter valued at about $165,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.